JP2023553216A5 - - Google Patents

Info

Publication number
JP2023553216A5
JP2023553216A5 JP2023559969A JP2023559969A JP2023553216A5 JP 2023553216 A5 JP2023553216 A5 JP 2023553216A5 JP 2023559969 A JP2023559969 A JP 2023559969A JP 2023559969 A JP2023559969 A JP 2023559969A JP 2023553216 A5 JP2023553216 A5 JP 2023553216A5
Authority
JP
Japan
Prior art keywords
genetically modified
polypeptide
composition according
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553216A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062484 external-priority patent/WO2022125711A1/en
Publication of JP2023553216A publication Critical patent/JP2023553216A/ja
Publication of JP2023553216A5 publication Critical patent/JP2023553216A5/ja
Pending legal-status Critical Current

Links

JP2023559969A 2020-12-09 2021-12-08 遺伝子操作細胞療法のための標的化サイトカイン構築物 Pending JP2023553216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123281P 2020-12-09 2020-12-09
US63/123,281 2020-12-09
PCT/US2021/062484 WO2022125711A1 (en) 2020-12-09 2021-12-08 Targeted cytokine construct for engineered cell therapy

Publications (2)

Publication Number Publication Date
JP2023553216A JP2023553216A (ja) 2023-12-20
JP2023553216A5 true JP2023553216A5 (cg-RX-API-DMAC7.html) 2024-12-10

Family

ID=81972793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559969A Pending JP2023553216A (ja) 2020-12-09 2021-12-08 遺伝子操作細胞療法のための標的化サイトカイン構築物

Country Status (8)

Country Link
US (1) US20240043490A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259213A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553216A (cg-RX-API-DMAC7.html)
KR (1) KR20230129983A (cg-RX-API-DMAC7.html)
CN (1) CN116829194A (cg-RX-API-DMAC7.html)
AU (1) AU2021397271A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201573A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022125711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
US20260022190A1 (en) * 2022-07-08 2026-01-22 Shenghe (China) Biopharmaceutical Co., Ltd. Heterodimeric fusion protein and use thereof
CA3262929A1 (en) * 2022-07-25 2024-02-01 Sloan-Kettering Institute For Cancer Research PREPARATION PROCESSES FOR ADOPTIVE CELL THERAPIES
CN121969385A (zh) * 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
CN117904196B (zh) * 2024-01-05 2024-07-12 安徽大学 一种非小细胞肺癌组蛋白h1.4赖氨酸乙酰化点突变细胞模型的构建及其应用
CN120943901A (zh) * 2025-05-29 2025-11-14 北京肿瘤医院(北京大学肿瘤医院) 经修饰的caix靶向环肽、核素标记物及其在肿瘤诊疗方面的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
CN118126157A (zh) * 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
MX387358B (es) * 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途

Similar Documents

Publication Publication Date Title
AU2023233125B2 (en) Anti-KRAS-G12D T cell receptors
AU2018342245B2 (en) Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation
Ghia et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22
TWI908730B (zh) 識別p53中之r175h或y220c突變之t細胞受體
TWI713798B (zh) 增加介白素-2(il-2)分泌量之方法和源自該方法之蛋白類
US10919950B2 (en) Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
JP2021502114A (ja) 改変された免疫細胞およびその使用
Mrózek et al. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells
KR20120093002A (ko) Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
JP2025163198A (ja) キメラサイトカイン受容体
US20250129169A1 (en) Surrogate cytokine polypeptides
JP2022520777A (ja) in vivoでの免疫細胞の増殖をブースト可能なアジュバント
CN114901684A (zh) 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子
TW201835100A (zh) 新穎t細胞受體
WO2024213695A1 (en) Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27
Liu et al. Insights into human CD34+ hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome
Chilakapati et al. Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma
CN119371485B (zh) 源自长链非编码rna slc12a5-as1的hla-a*11:01肾细胞癌肿瘤抗原短肽及其应用
CN119371486B (zh) 源自长链非编码rna linc02717的hla-a*11:01肾细胞癌肿瘤抗原短肽
Di Roberto et al. speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing
CN119751558B (zh) 源自长链非编码rna ensg00000286147的hla-a*24:02肾细胞癌肿瘤抗原短肽
WO2019122875A1 (en) Chimeric antigen receptor
CN119390792B (zh) 源自人逆转录病毒herv3895基因的hla-a*2402肾细胞癌肿瘤抗原短肽
CN113785201B (zh) 用于检测镍纹蛋白-β活性的方法
Bradl et al. The pre‐B cell receptor and its ligands–it takes two to tango